β‐Aryl Nitrile Construction<i>via</i>Palladium‐Catalyzed Decarboxylative Benzylation of α‐Cyano Aliphatic Carboxylate Salts
作者:Rui Shang、Zheng Huang、Xiao Xiao、Xi Lu、Yao Fu、Lei Liu
DOI:10.1002/adsc.201200383
日期:2012.9.17
The palladium‐catalyzed decarboxylative benzylation of α‐cyano aliphatic carboxylatesalts with benzyl electrophiles was discovered. This reaction exhibits good functional group compatibility and proceeds under relatively mild conditions. A diverse range of quaternary, tertiary and secondary β‐aryl nitriles can be conveniently prepared by this method.
Carbopalladation of Nitriles: Synthesis of Benzocyclic Ketones and Cyclopentenones via Pd-Catalyzed Cyclization of ω-(2-Iodoaryl)alkanenitriles and Related Compounds
作者:Alexandre A. Pletnev、Richard C. Larock
DOI:10.1021/jo0262006
日期:2002.12.1
An efficient procedure for the synthesis of 2,2-disubstituted benzocyclic ketones by intramolecular carbopalladation of nitriles has been developed. The cyclization of substituted 3-(2-iodoaryl)propanenitriles affords indanones in high yields. The reaction is compatible with a wide variety of functional groups. This methodology has been extended to the synthesis of tetralones and cyclopentenones.
(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER
申请人:Nexys Therapeutics, Inc.
公开号:EP3902796A1
公开(公告)日:2021-11-03
[EN] (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE (PYRIDIN-2-YL)AMINE UTILISÉS COMME INHIBITEURS DE TGF-BÊTA R1 (ALK5) POUR LE TRAITEMENT DU CANCER
申请人:NEXYS THERAPEUTICS INC
公开号:WO2020139636A1
公开(公告)日:2020-07-02
The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.